Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study

Affiliations

• ¹ Department of Hematology and Oncology, University Hospital Heidelberg, Heidelberg, Germany.
• ² Department of Hematology and Oncology, University Hospital Tuebingen, Tuebingen, Germany.
• ³ Department for Stem Cell Transplantation, University Hospital Hamburg, Hamburg, Germany.
• ⁴ Department of Hematology and Oncology, University Hospital Dresden, Dresden, Germany.
• ⁵ Department of Hematology, Cell Therapy and Hemostaseology, University Hospital Leipzig, Leipzig, Germany.
• ⁶ Department of Hematology and Oncology, University Hospital Mainz, Mainz, Germany.
• ⁷ Department of Hematology and Oncology, University Hospital Munich, Munich, Germany.
• ⁸ Department of Hematology and Oncology, University Hospital Schleswig-Holstein, Kiel, Germany.
• ⁹ Department of Hematology and Oncology, Klinikum Berlin-Buch, Berlin, Germany.
• ¹⁰ Department of Hematology and Oncology, University Hospital Freiburg, Freiburg, Germany.
• ¹¹ Department of Hematology and Oncology, University Hospital Erlangen, Erlangen, Germany.
• ¹² Department of Hematology and Oncology, Ruhr-University Bochum, Bochum, Germany.
• ¹³ Department of Hematology and Oncology, University Hospital Muenster, Muenster, Germany.
• ¹⁴ Department of Hematology and Oncology, University Hospital Wuerzburg, Wuerzburg, Germany.
• ¹⁵ Department of Hematology and Medical Oncology, University Medical Center Goettingen, Goettingen, Germany.